Syros Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 3.71 million compared to USD 23.79 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.85 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.58 USD | +5.08% |
|
-7.00% | -28.37% |
06-05 | Transcript : Syros Pharmaceuticals, Inc. - Shareholder/Analyst Call | |
05-14 | Transcript : Syros Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-28.37% | 149M | |
+34.14% | 51.12B | |
-6.54% | 39.4B | |
+34.92% | 38.48B | |
+12.62% | 26.36B | |
-12.11% | 26.22B | |
-13.43% | 20.96B | |
+43.73% | 14.02B | |
+31.81% | 12.49B | |
-4.54% | 11.61B |
- Stock Market
- Equities
- SYRS Stock
- News Syros Pharmaceuticals, Inc.
- Syros Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024